Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 2, 1997

View Archived Issues

Company Profile: Cor Therapeutics

Angiostatin production mechanism elucidated; may permit large-scale studies

Takeda's PAF antagonist evaluated in preclinical model of asthma

NaviCyte and SmithKline Beecham enter drug discovery collaboration

Genzyme Molecular Oncology, Parke-Davis enter genomics agreement

Genset sequences Chlamydia pneumoniae

Steroidal anticancer compounds isolated from C. africana

Fujisawa isolates novel calpain inhibitors

Heterocyclic antitumor agents from Dainippon

Novel adenosine antagonists revealed by Fujisawa

Almirall discloses new COX-2-selective compounds

Dopamine receptor subtype-specific ligands prepared at Neurogen

Potent, orally active gpIIb/IIIa receptor antagonist for once-daily administration

Recombinant IFN-beta-1a from Ares-Serono reduces relapses, delays progression in MS

Anticonvulsant activity of retigabine established in preclinical model

Potent antiamnesia activity reported for AChE inhibitor DHED

Second-generation 2-5A antisense drug with broad-spectrum anti-RSV activity

Virulizin interim phase I/II results in advanced pancreatic cancer

Y-27632: a smooth muscle relaxant that inhibits p160ROCK protein kinase

Long-lasting effects on memory impairment of M2 antagonist treatment in rats

Further labeling changes for Rezulin/Noscal; Romozin availability suspended in U.K.

Muse approved in U.K.

ALVAC-IL-12 gene therapy effective in murine model of breast cancer

Imitrex Nasal Spray now available in U.S.

Repligen: Q2 1998 highlights

MAbs to lymphocyte/endothelial adhesion molecules prevent diabetes in mouse model

Titan: Q3 1997 highlights

Dura terminates merger agreement with Scandipharm

Immunomedics enters distribution agreement with Lilly

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 2, 2026.
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...